Evidence map›Paper›PMID 28454801›Full record

Trial reportAmerican heart journal2017

Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL)-A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics.

REVEAL Collaborative Group, L Bowman, F Chen, E Sammons, J C Hopewell, K Wallendszus, W Stevens, E Valdes- Marquez, S Wiviott, C P Cannon and 3 more

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in American heart journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01252953 (REVEAL), which is not on this map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
8.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01252953 phase3active not recruitingnot on this map

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification. A Large-scale, Randomized Placebo-controlled Trial of the Clinical Effects of Anacetrapib Among People With Established Vascular Disease

TypeinterventionalSponsorUniversity of OxfordRan2011 to 2037Enrolled30,449ConditionsAtherosclerotic Cardiovascular DiseaseArmsAnacetrapib, Placebo anacetrapib
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 67 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Kidney as modulator and target of "good/bad" HDL.Pediatric nephrology (Berlin, Germany) · 2019
    Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Lipid management in patients with chronic kidney disease.Nature reviews. Nephrology · 2018 · on this map
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 1 country.

REVEAL Collaborative GroupREVEAL Central Coordinating Office, Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, United Kingdom.
L Bowman
F Chen
E Sammons
J C Hopewell
K Wallendszus
W Stevens
E Valdes- Marquez
S Wiviott
C P Cannon
E Braunwald
R Collins
M J Landray
University of Oxford · GB

Funding

British Heart Foundation FS/14/55/30806Medical Research Council MC_U137686861Medical Research Council MC_UU_12026/5
6 · The paper itself

Abstract

Patients with prior vascular disease remain at high risk for cardiovascular events despite intensive statin-based treatment. Inhibition of cholesteryl ester transfer protein by anacetrapib reduces low-density lipoprotein (LDL) cholesterol by around 25% to 40% and more than doubles high-density lipoprotein (HDL) cholesterol. However, it is not known if these apparently favorable lipid changes translate into reductions in cardiovascular events.

methodsThe REVEAL study is a randomized, double-blind, placebo-controlled clinical trial that is assessing the efficacy and safety of adding anacetrapib to effective LDL-lowering treatment with atorvastatin for an average of at least 4years among patients with preexisting atherosclerotic vascular disease. The primary assessment is an intention-to-treat comparison among all randomized participants of the effects of allocation to anacetrapib on major coronary events (defined as the occurrence of coronary death, myocardial infarction, or coronary revascularization).

resultsBetween August 2011 and October 2013, 30,449 individuals in Europe, North America, and China were randomized to receive anacetrapib 100mg daily or matching placebo. Mean (SD) age was 67 (8) years, 84% were male, 88% had a history of coronary heart disease, 22% had cerebrovascular disease, and 37% had diabetes mellitus. At the randomization visit (after at least 8weeks on a protocol-defined atorvastatin regimen), mean plasma LDL cholesterol was 61 (15) mg/dL and HDL cholesterol was 40 (10) mg/dL.

interpretationThe REVEAL trial will provide a robust evaluation of the clinical efficacy and safety of adding anacetrapib to an effective statin regimen. Results are anticipated in 2017.

Indexed as

AgedAnticholesteremic AgentsAtorvastatinCholesterol, HDLCholesterol, LDLCoronary DiseaseDouble-Blind MethodDrug Therapy, CombinationFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsIntention to Treat AnalysisMaleMiddle AgedOxazolidinonesResearch DesignanacetrapibAnticholesteremic AgentsAtorvastatinCholesterol, HDLCholesterol, LDLHydroxymethylglutaryl-CoA Reductase InhibitorsOxazolidinones

Identifiers

PMID28454801
PMCPMC5419667
OpenAlexW2590875878

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.